Molecular Targeted Radiopharmaceuticals Holding GmbH

MTR, founded in 2018, is an early stage company developing a new class of radiopharmaceuticals for Dx and Tx of solid tumors utilizing the overexpression of PARP-1 in tumor tissue. PARP is located on the DNA itself making PARP an ideal target for radionuclide based precision medicine. The precisely targeting of tumors with a radiolabeled PARP inhibitor offers both an unique diagnostic & staging potential and highly efficient & precisely targeted tumor therapy with minimal side effects. There continues to be a high unmet medical need for a potent anti-cancer therapy that includes efficacy against tumors that are currently poorly treatable or show multi-drug resistance. The MTR technology is deeply rooted in the theranostics principle in molecular medicine combining both diagnostic imaging and therapy with the same molecule being radiolabeled differently. This integrated companion approach deposits a highly targeted lethal payload to tumor tissue addressing even small therapy-resistant refractory lesions without systemic toxicity. Result: A new generation of targeted cancer Dx & Tx in a novel approach.